Elsevier has announced that six start-up companies have been selected from over 150 global applicants for The Hive, its innovation initiative for biotech and pharmaceutical start-ups.
Exscientia, LegoChem Biosciences, 4P-Pharma, Beacon Discovery, Sigilon Therapeutics, and Unum Therapeutics were selected by the global information analytics business, which specialises in science and health, for their commitment to cutting-edge science in emerging areas of research.
All of the start-ups were selected for demonstrating significant potential to impact how future treatments are researched and developed.
As members of The Hive, each company will receive support, complimentary training, and access to Elsevier’s suite of information solutions for 18 months.
The goal of The Hive is to help foster the discoveries that happen in start-up environments, ensuring that the route to market for new innovations is accelerated.
The six participating companies – the second intake of start-ups to The Hive – will use Elsevier’s tools to support their groundbreaking and innovative work in some of the most exciting research areas in pharma and biotech.
Betsy Davis, Senior Strategic Marketing Manager at Elsevier, said: “This year, to demonstrate the vast contribution of start-ups in the origin of drug discoveries, we will especially focus on helping these companies close the gap between concept and commercialisation – particularly for start-ups from academic backgrounds.”
Yong-Zu Kim, CEO and President, LegoChem Biosciences, said: “Being part of The Hive will increase the efficiency of our team’s research and development activities. Access to Elsevier’s R&D information and solutions will be a real boost to help us in achieving our aim of developing a new blockbuster drug.”
Andrew Hopkins, CEO, Exscientia, said: “We apply AI algorithms to drug design – one of our biggest challenges is systematic access to high quality data. Being part of The Hive and using a range of Elsevier’s tools will help us drive our research forward.”